Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 7/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14689781 | 0.99 | FFAR4 (0.44) | FFAR4KDM1ASCDMRGPRX4FFAR1 | |
| SCHEMBL2561940 | 0.77 | SLC6A4 (0.44) | SCDSLC6A4 | |
| Hydrochloric Acid SCHEMBL1230448 | 0.76 | SLC6A4 (0.43) | SCDSLC6A4 | |
| SCHEMBL22809546 | 0.74 | MRGPRX4 (0.43) | SCDMRGPRX4HTR2ASLC6A4KCNH2 | |
| SCHEMBL2564884 | 0.73 | SCD (0.49) | FFAR4KDM1ASCDHTR2ASLC6A4 | |
| SCHEMBL2564882 | 0.73 | SCD (0.49) | FFAR4KDM1ASCDHTR2ASLC6A4 | |
| SCHEMBL10313330 | 0.73 | MAP2K1 (0.51) | KDM1ASCDHTR2ASLC6A4 | |
| SCHEMBL9450780 | 0.73 | MGLL (0.45) | FFAR4SCDMRGPRX4FFAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL10276018 | 0.72 | MAP2K1 (0.50) | KDM1ASCDHTR2ASLC6A4 | |
| SCHEMBL3737321 | 0.70 | MRGPRX4 (0.45) | SCDMRGPRX4HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560963-B1 | PYRAZINE DERIVATIVES AS INHIBITORS OF THE ENZYME SCD-1 FOR THE TREATMENT OF CANCER DISEASES AND DIABETES | PF MEDICAMENT (FR) | 2016-10-05 | — | — | EP | disclosed |
| EP-2560963-B1 | PYRAZINE DERIVATIVES AS INHIBITORS OF THE ENZYME SCD-1 FOR THE TREATMENT OF CANCER DISEASES AND DIABETES | PF MEDICAMENT (FR) | 2016-10-05 | — | — | EP | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2560963-A1 | DERIVATIVES OF NITROGEN HETEROCYCLES, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN THERAPY | Pierre Fabre Médicament (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| WO-2011131593-A1 | DERIVATIVES OF NITROGEN HETEROCYCLES, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131593-A1 | DERIVATIVES OF NITROGEN HETEROCYCLES, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PRMT1, NNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FFAR4 3719/4885KDM1A 983/4885SCD 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.